Alzheimer’s Research Presentation by Dr. Huntington Potter, PHD

Dr. Huntington Potter, PhD, (center) Professor and Vice Chair for Basic Research in Neurology, Director of Alzheimer’s Disease Programs for the Linda Crnic Institute for Down Syndrome, and Director of the University of Colorado Rocky Mountain Alzheimer’s Disease Center. His laboratory seeks to identify and develop new therapies to stop Alzheimer’s disease, to reverse its cognitive effects, and to ultimately cure the disease forever. He is author of over 100 scientific articles and books, holds 16 patents, and his electron micrographs of DNA are on permanent exhibit in the Smithsonian Institute.

Dr. Huntington Potter, PhD, (center) Professor and Vice Chair for Basic Research in Neurology, Director of Alzheimer’s Disease Programs for the Linda Crnic Institute for Down Syndrome, and Director of the University of Colorado Rocky Mountain Alzheimer’s Disease Center. His laboratory seeks to identify and develop new therapies to stop Alzheimer’s disease, to reverse its cognitive effects, and to ultimately cure the disease forever. He is author of over 100 scientific articles and books, holds 16 patents, and his electron micrographs of DNA are on permanent exhibit in the Smithsonian Institute.

On May 17, 2016 Coloradans will have a chance to hear the latest advancements in research on the subjects of Alzheimer’s dementia and Down’s Syndrome and how the correlations between the two could lead us toward a cure. Renowned scientist, Huntington Potter, PhD, serves as Professor of Neurology and Vice Chair of Basic Research, and the Director of the Rocky Mountain Alzheimer’s Disease Center (RMADC). He and his staff represent vast medical-scientific expertise and work with state of the art technology at the University of Colorado Anschutz Medical Campus in Aurora.

Research for a cure is so important because the number of people diagnosed with dementia is staggering. In the U.S. there are 5.4 million people living with Alzheimer’s and the numbers are growing. In Colorado alone the number of people with Alzheimer’s will increase from 65,000 to 92,00 from 2016-2025, which is an increase of 41.5 percent. Today, one in three people are destined to have the disease.

“It is surprising how many people in Colorado are not aware that we have innovative research and ground breaking advances happening right here in our city. Breakthroughs from Dr. Potter’s team and their research are moving us close to effective new treatments, preventative therapies and possibly even a cure. We have the only such center of excellence in a 600-mile radius of Denver, “says Curt Foust of Home Instead Denver North, who along with Jill Lorentz of Summit Resilience Training is sponsoring Dr. Potter’s presentation at Crossroads Church, 9725 W. 50th Avenue in Wheat Ridge on May 17th.

Lorentz and Foust are teaming up to provide the best resources for families living with dementia in the metro area. Recently Lorentz helped Home Instead Denver North attain the recognition of Leader’s in Dementia Care through the Alzheimer’s Association, when she conducted 16, 8-hour training classes for their entire staff, arming them with techniques and strategies for working with people and families living with this disease. “I have been a supporter of Dr. Potter’s research since he came to Colorado in 2012,” said Lorentz. “At this time, medications for dementia are limited in their efficacy, so redirection skills, accompanied with knowledge of the person and their history to create activities and care plans to enhance their quality of life is our goal.” Lorentz goes on to say “bringing awareness to the need for continued research and new treatments is imperative. We are so fortunate to have such brilliant minds and a place to do their work, which starts with identifying predictors or bio markers of dementia in the lab, and then moving to clinical trials, which leads to potential new treatments. In addition, everything can transpire on one campus in one location, providing benefits straight from the laboratory to our community.” One such trial is happening right now. The RMADC’s first clinical trial testing the safety and efficacy of a current drug in mild to moderate Alzheimer’s disease (AD) is well underway. Dr. Potter and his researchers have identified the potential to stop, and possibly reverse the effects of AD in early animal models. Human clinical trials of this potential new AD therapy are currently underway. Dr. Potter soon hopes to launch a larger and longer trial to move this promising therapy closer to the market for individuals with AD During his presentation, Dr. Potter will also explain some of his other efforts to identify and advance new potential AD therapies.

“We are so excited to have a forum for Dr. Potter and his team to present their findings,” says Holly Foust, co-owner of Home Instead Denver North. After touring the RMDAC lab, Foust was amazed at the level of expertise and progressive research that was happening right here in our own back yard in Colorado.

Partnering to conquer Alzheimer’s disease, RMDAC, Home Instead Denver North and Summit Resilience Training are thankful for the opportunity to work together to create progress in the care of those with AD. This event is free of cost to attend, but our focus is to help monetarily support our local research. Donations are the single best accelerator of pushing us ever closer to our goal of a world free of Alzheimer’s disease. Space is limited, so please RSVP by calling 303-463-1900 or email info@summitresiliencetraining.com to secure your seat at the event and donate on May 17, 2016.

What: Alzheimer’s Research Presentation by Dr. Huntington Potter, PHD
Date: Tuesday, May 17, 2016
Time: 4:00 P.M.- 6:00P.M.
Where: Crossroads Church, 9725 W. 50th Avenue in Wheat Ridge, CO 80033
RSVP: 303-463-1900 or info@summitresiliencetraining.com


Warning: A non-numeric value encountered in /home/customer/www/myprimetimenews.com/public_html/wp-content/themes/PrimeTime/lib/builder-core/lib/layout-engine/modules/class-layout-module.php on line 499